

ACMT and AACT Position Statement: Preventing Occupational Fentanyl and Fentanyl Analog Exposure to Emergency Responders

Michael J. Moss¹ · Brandon J. Warrick² · Lewis S. Nelson³ · Charles A. McKay⁴ · Pierre-André Dubé⁵ · Sophie Gosselin⁶ · Robert B. Palmer⁷ · Andrew I. Stolbach⁸

Received: 2 August 2017 / Accepted: 10 August 2017 / Published online: 25 August 2017
© American College of Medical Toxicology 2017

The position of the American College of Medical Toxicology (ACMT) and American Academy of Clinical Toxicology (AACT), is as follows:

Fentanyl and its analogs are potent opioid receptor agonists, but the risk of clinically significant exposure to emergency responders is extremely low. To date, we have not seen reports of emergency responders developing signs or symptoms consistent with opioid toxicity from incidental contact with opioids. Incidental dermal absorption is unlikely to cause opioid toxicity. For routine handling of drug, nitrile gloves provide sufficient dermal protection. In exceptional circumstances where there are drug particles or droplets suspended in the air, an N95 respirator provides sufficient protection. Workers who may encounter fentanyl or fentanyl analogs should be trained to recognize the signs and symptoms of opioid intoxication, have naloxone readily available, and be trained to administer naloxone and provide active medical assistance. In the unlikely event of poisoning, naloxone should be administered to those with objective signs of hypoventilation or a depressed level of consciousness, and not

for vague concerns such as dizziness or anxiety. In the absence of prolonged hypoxia, no persistent effects are expected following fentanyl or fentanyl analog exposures. Those with small subclinical exposures and those who awaken normally following naloxone administration will not experience long-term effects. While individual practitioners may differ, these are the positions of American College of Medical Toxicology and American Academy of Clinical Toxicology at the time written, after a review of the issue and scientific literature.

Background

Fentanyl and fentanyl analogs are potent opioid receptor agonists. Fentanyl and its analogs are increasingly implicated in overdose and death in North America among illicit opioid users. The reported mortality from synthetic opioids rose 72.2% (to 9850) from 2014 to 2015 [1]. Due to limitations in identifying analogs, this figure likely underrepresents death from these drugs. Fentanyl analogs are distributed in North America both as substituted/adulterated powdered heroin and pressed into counterfeit tablet forms of opioids and other medications [2–4]. Authorities in the USA have reported seizures of a variety of these products including fentanyl, fentanyl precursors (e.g., N-phenyl-1-(2-phenylethyl) piperidin-4-amine), and different fentanyl analogs such as acetylfentanyl, butyrylfentanyl, and furanylfentanyl [4]. Other analogs, such as alfentanil, remifentanil, and sufentanil, are used in clinical practice.

Fentanyl is 50–100 times more potent than morphine at the mu-opioid receptor [5–8]. Carfentanil, an opioid developed for veterinary use, is 10,000 times more potent than morphine in animals, although it produces less apnea when dosed therapeutically [6, 9]. Despite its improved therapeutic index compared to morphine, very small errors in carfentanil dosing, not

✉ Andrew I. Stolbach
positionstatements@acmt.net

¹ Oregon Poison Center, Portland, OR, USA

² University of New Mexico, Albuquerque, NM, USA

³ Rutgers New Jersey Medical School, Newark, NJ, USA

⁴ University of Connecticut School of Medicine, Farmington, CT, USA

⁵ Institut national de santé publique du Québec, Quebec City, Québec, Canada

⁶ McGill University Health Center, Montreal, Québec, Canada

⁷ University of Colorado School of Medicine, Aurora, CO, USA

⁸ Johns Hopkins University, Baltimore, MD, USA

unexpected with illicitly distributed drugs, will result in lethal doses. There are limited pharmacological data on other analogs found in the illicit drug supply.

To date, there has been limited guidance for emergency responders. In June 2016, DEA published a warning to law enforcement on the dangers of fentanyl cautioning against field testing suspected fentanyl and recommending the use of gloves and a mask when such testing is conducted [10].

The US National Institute for Occupational Safety and Health (NIOSH, Centers for Disease Control) published a bulletin addressing potential danger to law enforcement, public health workers, and first responders who may be exposed to fentanyl or its analogs [11]. Citing an absence of empirical evidence, the NIOSH bulletin recommended use of a P100-rated respirator, nitrile gloves, and eye protection. For personnel performing tasks that may aerosolize fentanyl, the NIOSH bulletin recommended dermal protection such as coveralls or protective sleeves.

Given the prevalence of synthetic opioids, law enforcement and emergency medical services (EMS) agencies have become increasingly concerned about potential exposures while responding to medical calls, crime scenes, or during drug raids [10, 12, 13]. Reports of emergency responders developing symptoms after contact with these substances have described nonspecific findings such as “dizziness” or “feeling like body shutting down,” “dying” without objective signs of opioid toxicity such as respiratory depression [10]. Law enforcement and EMS must balance safety with mobility and efficiency when entering and securing potential scenes where drugs are used, distributed, or produced. We aim to address the risks of occupational exposures to ultra-potent opioids and the role of various types of personal protective equipment to reduce those risks.

Methodology

Our initial recommendations are based on the opinion and clinical experience of a task force of our members. In addition, the authors performed a literature search and drafted this position statement. This document was reviewed and approved by the ACMT Position Statement and Guidelines Committee, was sent to the ACMT Board of Directors, and then was sent to the entire College membership for review. After revision by the task force, final approval was made by the ACMT Board of Directors and AACT Board of Trustees.

Inhalation Exposure Risk for Fentanyl and Fentanyl Analogs

Inhalation is an exposure route of concern if drug particles are suspended in the air. Fentanyl has potentially high bioavailability (12–100%) by inhalation [14, 15]. It is highly

suspected that a weaponized aerosolized containing carfentanil and remifentanil were used to subdue hostage-takers of a Moscow theater in 2002. One hundred twenty-five died as a result of this weaponized aerosolized exposure [16]. Although an optimized airborne dispersal device is unlikely to be encountered in a local event, we considered such a scenario for respiratory protection.

Industrial producers of fentanyl use time-weighted average occupational exposure limits (OEL-TWA) for alfentanil (1 mcg/m^3), fentanyl (0.1 mcg/m^3), and sufentanil (0.032 mcg/m^3) to limit exposure [17]. At the highest airborne concentration encountered by workers, an unprotected individual would require nearly 200 min of exposure to reach a dose of 100 mcg of fentanyl.

The vapor pressure of fentanyl is very low ($4.6 \times 10^{-6} \text{ Pa}$) suggesting that evaporation of standing product into a gaseous phase is not a practical concern [18].

Dermal Exposure Risk for Fentanyl and Fentanyl Analogs

Fentanyl is amenable to transdermal absorption because of its low molecular weight and lipophilicity [19, 20]. Depending on the specific product, transdermal delivery systems (“patches”) take 3–13 h to produce a therapeutic serum fentanyl concentration and 35 h to reach peak concentration [21–24]. Absorption of liquid or aqueous fentanyl increases with larger surface area of application, duration of application, broken skin, and heat. The physical properties of fentanyl analogs are similar to fentanyl, suggesting potential for dermal absorption. In a small volunteer study, sufentanil citrate applied to the forearm and covered in an occlusive dressing was absorbed comparably to fentanyl, although exact bioavailability was not determined [25].

However, incidental dermal absorption is unlikely to cause opioid toxicity. If bilateral palmar surfaces were covered with fentanyl patches, it would take approximately 14 min to receive 100 mcg of fentanyl [using a body surface area of 17,000 cm^2 , palm surface area of 0.5% [26], and fentanyl absorption of 2.5 $\text{mcg/cm}^2/\text{h}$ [24]. This extreme example illustrates that even a high dose of fentanyl prepared for transdermal administration cannot rapidly deliver a high dose.

The above calculation is based on fentanyl patch data, which overestimates the potential exposure from drug in tablet or powder form in several ways. Drug must have sufficient surface area and moisture to be efficiently absorbed. Medicinal transdermal fentanyl utilizes a matrix designed to optimize delivery, whereas tablets and powder require dissolution for absorption. Relatedly, powdered drug sits on the skin, whereas patches have adhesive to hold drug in close proximity to the skin allowing both to remain moist. Finally,

in the above quoted figure, 2.5 mcg/cm²/h represents delivery at steady state after drug has penetrated the dermis, which overestimates the amount of absorption in the first few minutes of dermal exposure. This initial period is of most relevance in unintentional exposure, because fentanyl that is observed on skin can be rapidly removed by mechanical (brushing) means or cleansing with water. Therefore, based on our current understanding of the absorption of fentanyl and its analogs, it is very unlikely that small, unintentional skin exposures to tablets or powder would cause significant opioid toxicity, and if toxicity were to occur it would not develop rapidly, allowing time for removal.

Ocular-Facial Exposure Risk for Fentanyl and Fentanyl Analogs

Mucous membranes present opportunity for absorption of fentanyl and its analogs. Fentanyl, for example, exhibits greater than 30-fold absorption across mucous membranes when compared to skin and is available in a formulation that utilizes transmucosal administration [27]. A healthy male veterinarian was splashed in the eyes and mouth with contents of a dart containing 1.5 mg of carfentanil and 50 mg xylazine. Despite immediately washing his face with water, he became drowsy within 2 min; he responded promptly to the administration of naloxone [28]. It is not clear to what extent these effects were a result of carfentanil exposure. Although facial contact with liquid or powder opioids is unlikely, OSHA rated splash protection would be sufficient to prevent mucous membrane exposure.

Naloxone

Naloxone, a mu-opioid receptor antagonist, administered by parenteral, or intranasal routes, reverses opioid-related respiratory depression. The effective dose of naloxone depends on the patient's weight, amount of opioid to be reversed, and relative binding affinities at the mu receptor [8, 29]. There is scant information on human and animal naloxone reversal of fentanyl analogs. Despite anecdotal reports that higher-than-usual doses may be necessary [30], animal data suggest that standard doses of naloxone should be sufficient to reverse carfentanil [31]. While a detailed discussion of dosing and administration of naloxone is beyond the scope of this guideline, if a patient does not respond to 10 mg of naloxone, it is unlikely additional naloxone will be of value [29]. For patients who are hypoventilating and unresponsive to initial doses of naloxone, promptly assisting ventilation and oxygenation are recommended.

Recommendations

The American College of Medical Toxicology and American Academy of Clinical Toxicology recognize the challenges in issuing recommendations where available data are incomplete. We believe that recommendations should be protective of emergency responders, but not result in unnecessary delays in care to patients with time-sensitive conditions. We also recognize that PPE can interfere with task performance by emergency responders and law enforcement officials. Due to the limited available data, the following recommendations primarily represent consensus expert opinion.

General Precautions and Management of Exposure

- Workers who may encounter fentanyl or fentanyl analogs should be trained to recognize the symptoms and objective signs of opioid intoxication, should have naloxone readily available, and should be trained to administer naloxone.
- For opioid toxicity to occur, the drug must enter the blood and brain from the environment. Toxicity cannot occur from simply being in proximity to the drug.
- Toxicity may occur in canines utilized to detect drug. The risks are not equivalent to those in humans given the distinct contact that dogs, and not humans, have with the local environment.

Dermal Precautions

- Incidental dermal absorption is very unlikely to cause opioid toxicity. For routine handling of drug, nitrile gloves provide sufficient dermal protection.
- In situations where an enclosed space is potentially heavily contaminated with a highly potent opioid, water resistant coveralls should be worn.
- Incidental dermal exposures should immediately be washed with water. Alcohol-based hand sanitizers should not be used for decontamination as they do not wash opioids off the skin and may increase dermal drug absorption.

Respiratory Precautions

- In the unusual circumstance of significant airborne suspension of powdered opioids, a properly fitted N95 respirator or P100 mask is likely to provide reasonable respiratory protection.

Mucous Membrane/Splash Exposure

- OSHA-approved protection for eyes and face should be used during tasks where there exists possibility of splash to the face.

Naloxone Administration and Airway Management

- Naloxone should be administered to those with objective signs of hypoventilation from opioid intoxication.
- If hypoventilation persists following initial naloxone dose and personnel with advanced airway training are not available, repeat naloxone until reversal is seen or 10 mg is administered.
- Personnel with advanced airway training should provide airway support for patients who are in extremis or those who do not improve with naloxone.

Long-term Sequelae of Exposure

- In the absence of prolonged hypoxia, no persistent effects are expected following fentanyl or fentanyl analog exposures. Those with small subclinical exposures and those who awaken normally following naloxone administration will not experience long-term effects.

Acknowledgments The authors would like to acknowledge the following for contributions to the statement: Jeffrey Brent, Robert N.E. French, Howard Greller, and Adam Rowden

Sources of Funding None.

Compliance with Ethical Standards

Conflicts of Interest None.

References

- Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. *MMWR Morb Mortal Wkly Rep.* 2016;65(5051):1445–52.
- Miller JM, Stogner JM, Miller BL, Blough S. Exploring synthetic heroin: accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders. *Drug and Alcohol Review* 2017.
- Diaz Bode A, Singh M, Andrews J, Kapur GB, Baez A. Fentanyl laced heroin and its contribution to a spike in heroin overdose in Miami-Dade County. *Am J Emerg Med* 2017.
- Drug Enforcement Agency. DEA Intelligence Brief. Counterfeit prescription pills containing fentanyls: a global threat. 2016. <https://www.dea.gov/docs/Counterfeit%20Prescription%20Pills.pdf>. Accessed May 6 2017.
- Higashikawa Y, Suzuki S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure-analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues. *Forensic Toxicology.* 2008;26:1–5.
- Janssen PA. Potent, new analgesics, tailor-made for different purposes. *Acta Anaesthesiol Scand.* 1982;26(3):262–8.
- Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. *Clin Pharmacokinet.* 1983;8(5):422–46.
- Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T et al. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. 2011.
- Wax PM, Becker CE, Curry SC. Unexpected “gas” casualties in Moscow: a medical toxicology perspective. *Ann Emerg Med.* 2003;41(5):700–5.
- Drug Enforcement Agency. DEA warning to police and public: fentanyl exposure kills. 2016. <https://www.dea.gov/divisions/hq/2016/hq061016.shtml>. Accessed May 6 2016.
- National Institute for Occupational Safety and Health. Fentanyl: preventing occupational exposure to emergency responders. 2016. <https://www.cdc.gov/niosh/topics/fentanyl/risk.html>. Accessed May 6 2017.
- McDaniels A. Deputy, two EMS providers treated for overdose symptoms responding to call. *The Baltimore Sun, Baltimore, MD.* 2017. <http://www.baltimoresun.com/health/bs-md-harford-opioid-exposure-20170523-story.html>. Accessed May 27 2017.
- Greenslade B. 3 Winnipeg police officers possibly exposed to fentanyl, self-administer naloxone. *Global News* 2017.
- Hung OR, Whynt SC, Varvel JR, Shafer SL, Mezei M. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. *Anesthesiology.* 1995;83:277–84.
- Mather LE, Woodhouse A, Ward ME, Farr SJ, Rubsam RA, Eltherington LG. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. *Br J Clin Pharmacol.* 1998;46:37–43.
- Riches JR, Read RW, Black RM, Cooper NJ, Timperley CM. Analysis of clothing and urine from Moscow theatre siege casualties reveals carfentanil and remifentanil use. *J Anal Toxicol.* 2012;36(9):647–56.
- Van Nimmen NFJ, Poels KLC, Veulemans HAF. Identification of exposure pathways for opioid narcotic analgesics in pharmaceutical production workers. *Ann Occup Hyg.* 2006;50:665–77.
- Gupta PK, Ganesan K, Gutch PK, Manral L, Dubey DK. Vapor pressure and enthalpy of vaporization of fentanyl. *J Chem Eng Data.* 2008;53(3):841–5.
- Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. *Br J Pharmacol.* 2015;172(9):2179–209.
- Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. *J Med Toxicol.* 2009;5(4):230–41.
- Duthie DJ, Rowbotham DJ, Wyld R, Henderson PD, Nimmo WS. Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. *Br J Anaesth.* 1988;60:614–8.
- Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Gaukroger P, Cousins MJ. The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. *Pain.* 1989;37:193–202.
- Miguel R, Kreitzer JM, Reinhart D, Sebel PS, Bowie J, Freedman G, et al. Postoperative pain control with a new transdermal fentanyl delivery system. A multicenter trial. *Anesthesiology.* 1995;83:470–7.
- Product Information: Duragesic (fentanyl transdermal system) for transdermal administration. Janssen Pharmaceuticals 2016. https://www.janssenmd.com/pdf/duragesic/duragesic_pi.pdf. Accessed May 7 2017.

25. Sebel PS, Barrett CW, Kirk CJC, Heykants J. Transdermal absorption of fentanyl and sufentanil in man. *Eur J Clin Pharmacol.* 1987;32:529–31.
26. Rhodes J, Clay C, Phillips M. The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta-analysis. *Br J Dermatol.* 2013;169(1):76–84.
27. Roy SD, Flynn GL. Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. *Pharm Res.* 1990;7(8):842–7.
28. George AV, Lu JJ, Pisano MV, Metz J, Erickson TB. Carfentanil—an ultra potent opioid. *Am J Emerg Med.* 2010;28(4):530–2.
29. Boyer EW. Management of opioid analgesic overdose. *N Engl J Med.* 2012;367(2):146–55.
30. Gussow L. Who said the opioid crisis couldn't get any worse? *Emerg Med News.* 2016;38(11):1–29.
31. Moresco A, Larsen RS, Sleeman JM, Wild MA, Gaynor JS. Use of naloxone to reverse carfentanil citrate-induced hypoxemia and cardiopulmonary depression in Rocky Mountain wapiti (*Cervus elaphus nelsoni*). *J Zoo Wildl Med.* 2001;32(1):81–9.